You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
A single-cell "atlas" of pathologically normal breast tissue was presented by an MD Anderson Cancer Center representative at the AACR's online annual meeting this week.
The firm recently published a paper with its sibling company HiFiBio on antibody sequencing, but is looking to develop more applications.
The researchers, from various institutions in China, said they hope their data will contribute to the completion of the international Human Cell Atlas project.
The group will use IsoPlexis' single-cell proteomics platform to analyze immune cells from patients who have been diagnosed or recovered from COVID-19.
The financing was led by HealthQuest Capital, with participation from 5AM Ventures and RareCyte founder Ron Seubert, and follows a $30 million round in 2017.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
Using a single-nucleus RNA sequencing strategy, investigators tracked down cell type-specific gene expression and networks in Alzheimer's brains.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.